ModelEdge

Scinai Immunotherapeutics Ltd
SCNI
Filing Type20-F
Filing Date5/14/2024
Updated5/15/24, 2:01 PM

Filing

20-F
Earnings Release

Exhibits

20-FAnnual and Transition Report of Foreign Private Issuers
EX-2.3DESCRIPTION OF SHARE CAPITAL
EX-12.1CERTIFICATION
EX-12.2CERTIFICATION
EX-13.1CERTIFICATION
EX-13.2CERTIFICATION
EX-15.1CONSENT OF KESSELMAN & KESSELMAN, CERTIFIED PUBLIC ACCOUNTANT (ISR.), A MEMBER FIRM OF PRICEWATERHOUSECOOPERS INTERNATIONAL LIMITED, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE REGISTRANT
EX-15.2CONSENT OF KOST FORER GABBAY & KASIERER, CERTIFIED PUBLIC ACCOUNTANT (ISR.), A MEMBER OF ERNST & YOUNG GLOBAL, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE REGISTRANT
EX-16.1LETTER, FROM KOST FORER GABBAY & KASIERER, CERTIFIED PUBLIC ACCOUNTANT (ISR.), A MEMBER OF ERNST & YOUNG GLOBAL, TO THE SECURITIES AND EXCHANGE COMMISSION, DATED, MAY 15, 2024
EX-97.1SCINAI IMMUNOTHERAPEUTICS POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION
GRAPHICGraphic
GRAPHICGraphic
GRAPHICGraphic
GRAPHICGraphic
GRAPHICGraphic